United States Patent 9,795,672: Bevacizumab Dose Continuation After Grade III Hypertensive Event With Antihypertensive Management
What is claimed, in operational terms?
US Patent 9,795,672 claims a treatment method for cancer patients who develop a Grade III hypertensive event after receiving bevacizumab, where clinicians manage the hypertension with an antihypertensive agent while continuing bevacizumab without altering the dose regimen.
Claim 1 (core claim)
A method of treating cancer comprising:
- administering bevacizumab to a patient
- where the patient has a Grade III hypertensive event resulting from bevacizumab administration
- then administering an antihypertensive agent in an amount sufficient to manage that Grade III event
- while continuing bevacizumab and doing so without altering the dosage regimen.
Dependent claim scope that expands the therapeutic setting
- Claim 2: adds one or more chemotherapeutic agents.
- Claims 3-6: restrict the chemo options to specific classes, then specific agents:
- Claim 3: alkylating agent; antimetabolite; pyrimidine analog; vinca alkyloid; epipodophyllotoxin; antibiotic; topoisomerase inhibitor; interferon; platinum coordination complex; taxoid
- Claim 4: specifies agents including 5-FU, leucovorin, irinotecan, paclitaxel, oxaliplatin, carboplatin, cisplatin, doxorubicin, topotecan, interferon-alpha
- Claim 5: limits to one or more of 5-FU, leucovorin, irinotecan, oxaliplatin
- Claim 6: narrows further to 5-FU, leucovorin, and irinotecan together
- Claim 7: limits cancers to a long list including colorectal, rectal, glioblastoma, NSCLC, cervical, peritoneum, renal, ovarian, mesothelioma.
- Claims 8-13: narrow to specific metastatic indications:
- Claim 8/9: metastatic colorectal cancer (and depends on Claim 6)
- Claim 10: metastatic NSCLC
Claims 11-12: metastatic cervical and metastatic ovarian/peritoneum
- Claim 13: metastatic renal
- Claim 14: cancer is glioblastoma.
- Claims 15 and 18: specify bevacizumab schedules/doses:
- Claim 15: bi-weekly about 10 mg/kg
- Claim 18: bi-weekly about 5 mg/kg
- Claim 16: patient does not have clinically significant cardiovascular disease prior to bevacizumab.
- Claim 17: where one chemo agent is 5-FU (depends on Claim 8).
What does the patent try to protect, beyond generic hypertension control?
The claim is not simply “treat hypertension.” It is the clinical sequence and constraint:
- Bevacizumab is administered.
- A Grade III hypertensive event occurs.
- The clinician administers an antihypertensive agent sufficient to manage the event.
- Bevacizumab is continued with no dosage regimen change.
This is a risk-management continuation strategy: it protects continuation of bevacizumab despite a severe hypertension toxicity, as long as management occurs and dosing is not altered.
Why the “no dose alteration” constraint matters for novelty
If prior art teaches dose interruption, dose reduction, or discontinuation after severe hypertension, it does not land directly on the claimed method. The claim requires continuation “without altering the dosage regimen.” That creates a narrower infringement hook than general “manage blood pressure in patients receiving bevacizumab.”
Claim coverage map: key “decision points” a court would parse
| Claim element |
What must be shown for infringement (practically) |
How it narrows scope |
| Bevacizumab administration |
Patient receives bevacizumab |
Baseline |
| “Grade III hypertensive event resulting from bevacizumab” |
The event is causally attributable to bevacizumab |
Requires causality framing in practice |
| Antihypertensive agent sufficient to manage Grade III |
There is a therapeutic step to manage severity |
Stops short of prophylaxis-only strategies |
| Continued bevacizumab with “no altered dosage regimen” |
Dosing schedule/dose remains unchanged after the Grade III event |
Excludes interruptions/reductions/discontinuation scenarios |
| Optional chemo combinations and specific agents |
Additional agents used in the regimen |
Limits combination infringement |
| Optional cancer types (including metastatic categories) |
Indication-specific limitation |
Limits reach to defined clinical contexts |
| Specific bevacizumab dose levels and schedule |
Bi-weekly dosing at ~5 mg/kg or ~10 mg/kg |
Further narrows to certain regimens |
What are the most vulnerable claim features?
1) “Grade III hypertensive event resulting from bevacizumab”
A patent that asserts causation at the clinical level can face validity and enforcement friction when prior art documents use broader toxicity management language (or when clinical practice treats hypertension as a bevacizumab-associated AE without asserting “resulting from” at the method level).
2) “Continue bevacizumab without altering the dosage regimen”
This is an operational constraint that many clinical guidelines and label directions use as a trigger for dose interruption, reduction, or discontinuation for severe AEs. If prior art aligns with the same management outcome but uses interruption, it may not anticipate. If prior art teaches continuation under certain management conditions but with some flexibility on dosing, the claim may be vulnerable on definiteness and on enablement-style challenges.
3) Combination chemo specificity (e.g., 5-FU/leucovorin/irinotecan)
Broad oncology practice already uses these agents. But infringement of narrower dependent claims depends on which chemo regimen was actually used in the method. That can shrink enforceable scope relative to the broadest claim.
4) Bi-weekly dosing at “about 5 mg/kg” or “about 10 mg/kg”
The dosing specificity may capture only a subset of bevacizumab regimens used across indications. If competitors use other schedules or mg/kg ranges, they can design around dependent claims while potentially still implicating Claim 1.
Patent landscape: where competitive freedom usually concentrates
Because the claim is framed as a specific AE management continuation strategy, freedom-to-operate in the US typically hinges on whether there are:
1) Earlier patents disclosing bevacizumab continuation after severe hypertension with antihypertensive therapy, and/or
2) Earlier patents disclosing prophylaxis and management of hypertension during VEGF-inhibitor therapy coupled with continuation, and/or
3) Label-anchored standard-of-care disclosures (FDA label and guideline language) that describe managing hypertension while maintaining bevacizumab under specified thresholds.
However, the request is to analyze “the patent landscape” for US 9,795,672, and to do it properly requires identifying the patent’s priority/filing date, publication history, and the cited references and family members. Those elements are not provided. Without them, the landscape cannot be mapped to specific earlier US patents, office actions, or litigation patterns with the level of specificity required for investment-grade conclusions.
Given the constraints, a complete and accurate landscape analysis cannot be produced from the claim text alone.
Critical assessment of enforceability posture (based on claim drafting)
Even without the prosecution history, the claim structure implies a strategy to capture a narrow but repeatable clinical practice:
- The independent claim (Claim 1) is broad on:
- cancer type (via dependent Claim 7, but Claim 1 itself is not limited to a specific cancer)
- choice of antihypertensive agent (not specified)
- choice of chemo regimen (not specified in Claim 1)
- The dependent claims then narrow the population and regimen to increase coverage across specific oncology standards (CRC and metastatic settings in particular).
Practical enforcement likely centers on combination therapy and metastatic CRC
Dependent Claim 6 specifically recites 5-FU, leucovorin, and irinotecan, which aligns with common CRC regimens (with or without bevacizumab depending on protocol). That makes Claim 6 a likely target for infringement arguments in settings where clinicians keep bevacizumab at the same regimen after severe hypertension, provided management is implemented.
Design-around options competitors would evaluate
- Alter the dose regimen after the Grade III event (pause, reduce, or otherwise change the regimen) to avoid the “without altering” constraint.
- Treat and document hypertension management but also interrupt bevacizumab dosing as required by their protocol or label/guideline interpretations.
- Use different dosing schedules outside the dependent-dose claims (bi-weekly ~5 mg/kg or ~10 mg/kg), though Claim 1 could still cover other schedules if it is read as dose-regimen agnostic.
Key Takeaways
- The patent protects a continuation strategy: after a bevacizumab-associated Grade III hypertensive event, clinicians manage with an antihypertensive agent but continue bevacizumab without altering the dosage regimen.
- Dependent claims significantly narrow the method to specific chemotherapies and metastatic oncology indications, with notable focus on 5-FU/leucovorin/irinotecan combinations and metastatic CRC settings.
- The strongest litigation-enabling feature is the “no dosage regimen alteration” constraint; the strongest vulnerabilities for competitors are any label-consistent interruption/reduction practices and any protocols that modify bevacizumab dosing after Grade III hypertension.
- A true US patent landscape map (specific earlier US patents, priority chain conflicts, and examiner-cited references) cannot be completed from claim text alone.
FAQs
1) What is the single most important technical limitation in Claim 1?
Bevacizumab is continued after a bevacizumab-associated Grade III hypertensive event while an antihypertensive agent manages the event, and the bevacizumab dosage regimen is not altered.
2) Does the patent require a particular antihypertensive drug?
No. Claim 1 requires an antihypertensive agent sufficient to manage the Grade III event but does not specify drug identity.
3) Are the cancer types restricted?
Claim 1 is not limited to a specific cancer in the text provided, but dependent Claim 7 restricts cancer types (e.g., colorectal, glioblastoma, NSCLC, cervical, peritoneum, renal, ovarian, mesothelioma). Dependent claims 8-14 add further narrowing to metastatic colorectal and other metastatic subsets.
4) Which chemotherapy regimen is explicitly required by a dependent claim?
Claim 6 requires 5-FU, leucovorin, and irinotecan together.
5) Can competitors avoid infringement by pausing bevacizumab?
If bevacizumab is paused or its dosing regimen is changed after the Grade III hypertensive event, it can fall outside the claim requirement that continued treatment occurs without altering the dosage regimen.
References
[1] United States Patent 9,795,672 (claims as provided in prompt).
